Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (11/09/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Classification of Pediatric Myeloid Malignancies

Added text about the presentation, incidence, and outcome of patients with acute myeloid leukemia (AML) and t(16;21)(q24;q22) (RUNX1-CBFA2T3 AML) (cited Noort et al. as reference 72).

Added text about the presentation, incidence, and outcome of patients with AML and t(16;21)(p11;q22) (FUS-ERG AML).

Chronic Myelogenous Leukemia (CML)

Revised text about the U.S. Food and Drug Administration indications for the use of nilotinib in treating children with CML. Also updated text about the safety profile of nilotinib in children.

Added text about the results of a phase II study of dasatinib in 29 children who were resistant or intolerant to imatinib.

Added text to state that in two pediatric studies of nilotinib, 21 of 44 children with CML who were resistant or intolerant to other TKIs achieved major molecular responses at a median of 2.8 months; none of the 21 patients lost their major molecular response after a median of 11.3 months of follow-up.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Survivorship and Adverse Late Sequelae

Next section >
About This PDQ Summary